JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Single Nucleotide Polymorphisms in STAT3 and STAT4 and Risk of Hepatocellular Carcinoma in Thai Patients with Chronic Hepatitis B
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Single Nucleotide Polymorphisms in STAT3 and STAT4 and Risk of Hepatocellular Carcinoma in Thai Patients with Chronic Hepatitis B
Chanthra, Nawin; Payungporn, Sunchai; Chuaypen, Natthaya; Piratanantatavorn, Kesmanee; Pinjaroen, Nutcha; Poovorawan, Yong; Tangkijvanich, Pisit;
  PDF(new window)
 Abstract
Hepatitis B virus (HBV) infection is the leading cause of hepatocellular carcinoma (HCC) development. Recent studies demonstrated that single nucleotide polymorphisms (SNPs) rs2293152 in signal transducer and activator of transcription 3 (STAT3) and rs7574865 in signal transducer and activator of transcription 4 (STAT4) are associated with chronic hepatitis B (CHB)-related HCC in the Chinese population. We hypothesized that these polymorphisms might be related to HCC susceptibility in Thai population as well. Study subjects were divided into 3 groups consisting of CHB-related HCC (n
 Keywords
Chronic hepatitis B;hepatocellular carcinoma;STAT3;STAT4;single nucleotide polymorphisms;
 Language
English
 Cited by
1.
Interleukin-6-174 Promoter Polymorphism and Susceptibility to Hepatitis B Virus Infection as a Risk Factor for Hepatocellular Carcinoma in Iran,;;;

Asian Pacific Journal of Cancer Prevention, 2016. vol.17. 5, pp.2395-2399 crossref(new window)
2.
Tumor Necrosis Factor Alpha -308 G/A Single Nucleotide Polymorphism and Susceptibility to Hepatocellular Carcinoma Via Hepatitis B Infection,;;;;

Asian Pacific Journal of Cancer Prevention, 2016. vol.17. 7, pp.3381-3384 crossref(new window)
1.
Meta-analysis reveals an association between signal transducer and activator of transcription-4 polymorphism and hepatocellular carcinoma risk, Hepatology Research, 2016, 47, 4, 303  crossref(new windwow)
 References
1.
Bruix J, Sherman M (2005). Diagnosis of Small HCC. Gastroenterology, 129, 1364. crossref(new window)

2.
Chen K, Shi W, Xin Z, et al (2013). Replication of genome wide association studies on hepatocellular carcinoma susceptibility Loci in a chinese population. PLoS One, 8, 77315. crossref(new window)

3.
Clark A, Gerlach F, Tong H, et al (2013). A trivial role of STAT4 variant in chronic hepatitis B induced hepatocellular carcinoma. Infect Genet Evol, 18, 257-61. crossref(new window)

4.
He G, Karin M (2011). NF-kappaB and STAT3-key players in liver inflammation and cancer. Cell Res, 21, 159-68. crossref(new window)

5.
He G, Yu GY, Temkin V, et al (2010). Hepatocyte IKKbeta/ NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell, 17, 286-97. crossref(new window)

6.
Hirano T, Ishihara K, Hibi M (2000). Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene, 19, 2548-56. crossref(new window)

7.
Hirschfield GM, Liu X, Xu C, et al (2009). Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med, 360, 2544-55. crossref(new window)

8.
Horras CJ, Lamb CL, Mitchell KA (2011). Regulation of hepatocyte fate by interferon-gamma. Cytokine Growth Factor Rev, 22, 35-43. crossref(new window)

9.
Hu K, Yang P, Jiang Z, et al (2010). STAT4 polymorphism in a Chinese Han population with Vogt-Koyanagi-Harada syndrome and Behcet's disease. Hum Immunol, 71, 723-6. crossref(new window)

10.
Hu Y, Ding N, Jin X, et al (2014). Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab. Cancer Cell Int, 14, 25. crossref(new window)

11.
Jiang DK, Sun J, Cao G, et al (2013). Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet, 45, 72-5. crossref(new window)

12.
Kim LH, Cheong HS, Namgoong S, et al (2015). Replication of genome wide association studies on hepatocellular carcinoma susceptibility loci of STAT4 and HLA-DQ in a Korean population. Infect Genet Evol, 33, 72-6. crossref(new window)

13.
Kimchi-Sarfaty C, Oh JM, Kim IW, et al (2007). A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science, 315, 525-8. crossref(new window)

14.
Korman BD, Kastner DL, Gregersen PK, et al (2008). STAT4: genetics, mechanisms, and implications for autoimmunity. Curr Allergy Asthma Rep, 8, 398-403. crossref(new window)

15.
Lee YH, Yun Y (1998). HBx protein of hepatitis B virus activates Jak1-STAT signaling. J Biol Chem, 273, 25510-5. crossref(new window)

16.
Nguyen KB, Watford WT, Salomon R, et al (2002). Critical role for STAT4 activation by type 1 interferons in the interferongamma response to viral infection. Science, 297, 2063-6. crossref(new window)

17.
O'Shea JJ, Holland SM, Staudt LM (2013). JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med, 368, 161-70. crossref(new window)

18.
Perz JF, Armstrong GL, Farrington LA, et al (2006). The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol, 45, 529-38. crossref(new window)

19.
Ramakrishna G, Rastogi A, Trehanpati N, et al (2013). From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence. Liver Cancer, 2, 367-83. crossref(new window)

20.
Remmers EF, Plenge RM, Lee AT, et al (2007). STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med, 357, 977-86. crossref(new window)

21.
Saha B, Jyothi Prasanna S, Chandrasekar B, et al (2010). Gene modulation and immunoregulatory roles of interferon gamma. Cytokine, 50, 1-14. crossref(new window)

22.
Sansone P, Bromberg J (2012). Targeting the interleukin-6/ Jak/stat pathway in human malignancies. J Clin Oncol, 30, 1005-14. crossref(new window)

23.
Sato K, Shiota M, Fukuda S, et al (2009). Strong evidence of a combination polymorphism of the tyrosine kinase 2 gene and the signal transducer and activator of transcription 3 gene as a DNA-based biomarker for susceptibility to Crohn's disease in the Japanese population. J Clin Immunol, 29, 815-25. crossref(new window)

24.
Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, et al (2007). Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res, 67, 9609-12. crossref(new window)

25.
Sopipong W, Tangkijvanich P, Payungporn S, et al (2013). The KIF1B (rs17401966) single nucleotide polymorphism is not associated with the development of HBV-related hepatocellular carcinoma in Thai patients. Asian Pac J Cancer Prev, 14, 2865-9. crossref(new window)

26.
Subramaniam A, Shanmugam MK, Perumal E, et al (2013). Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochim Biophys Acta, 1835, 46-60.

27.
Takeda K, Akira S (2000). STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev, 11, 199-207. crossref(new window)

28.
Thierfelder WE, van Deursen JM, Yamamoto K, et al (1996). Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature, 382, 171-4. crossref(new window)

29.
Wang C, Yang W, Yan HX, et al (2012). Hepatitis B virus X (HBx) induces tumorigenicity of hepatic progenitor cells in 3,5-diethoxycarbonyl-1,4-dihydrocollidine-treated HBx transgenic mice. Hepatology, 55, 108-20. crossref(new window)

30.
Wang SH, Yeh SH, Lin WH, et al (2009). Identification of androgen response elements in the enhancer I of hepatitis B virus: a mechanism for sex disparity in chronic hepatitis B. Hepatology, 50, 1392-402. crossref(new window)

31.
Waris G, Siddiqui A (2002). Interaction between STAT-3 and HNF-3 leads to the activation of liver-specific hepatitis B virus enhancer 1 function. J Virol, 76, 2721-9. crossref(new window)

32.
Xie J, Zhang Y, Zhang Q, et al (2013). Interaction of signal transducer and activator of transcription 3 polymorphisms with hepatitis B virus mutations in hepatocellular carcinoma. Hepatology, 57, 2369-77. crossref(new window)

33.
Yang JD, Roberts LR (2010). Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol, 7, 448-58. crossref(new window)

34.
Yu H, Pardoll D, Jove R (2009). STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer, 9, 798-809. crossref(new window)